| | Variable | Control group () | Intervention group () |
| | Gender | | | | Female, (%) | 11 (36.7) | 13 (40.6) | | Age, mean (SD) | 54.00 ± 8.690 | 56.63 ± 7.088 | | Duration of hemodialysis, months, Md (Q1, Q3) | 48.00 (20.50, 72.50) | 27.50 (13.00, 75.00) | | BMI | 23.08 ± 1.286 | 22.96 ± 1.300 | | Kt/V | 1.842 ± 0.02394 | 1.835 ± 0.02258 | | URR | 71.44 ± 2.356 | 72.83 ± 3.304 | | Primary disease diagnosis | | | | Chronic glomerulonephritis | 15 50 | 17 53.1 | | Diabetic nephropathy | 7 23.3 | 8 25 | | Hypertensive nephropathy | 5 16.7 | 5 15.6 | | Other primary diseases | 3 10 | 2 6.3 | | Visual analogue scale | 5.600 ± 2.127 | 5.750 ± 2.032 | | Calcium (mmol/L) | 2.386 ± 0.3083 | 2.479 ± 0.3523 | | Phosphorus (mmol/L) | 2.246 ± 0.6625 | 2.134 ± 0.5149 | | PTH (pg/L) Md (Q1, Q3) | 239.0 (98.90, 435.5) | 189.0 (92.90, 339.0) | | Histamine (ng/mL) Md (Q1, Q3) | 1.363 (0.524, 2.457) | 0.897 (0.250, 2.349) | | Substance P (pg/mL) Md (Q1, Q3) | 10.81 (4.336, 22.59) | 10.79 (5.094, 16.23) | | PAR-2 (ng/mL) Md (Q1, Q3) | 1.748 (0.828, 3.638) | 1.927 (0.860, 3.884) | | Tryptase (pg/mL) Md (Q1, Q3) | 306.2 (148.7, 442.5) | 371.1 (204.8, 524.0) |
|
|
